Can we prevent donor-specific antibodies from developing after ABO-incompatible kidney transplantation?

Area of Science:

• Nephrology
• Immunology
• Transplantation

Background:

• Chronic kidney disease and end-stage kidney disease (ESKD) present a growing global health challenge.
• Kidney transplantation is the optimal treatment for ESKD, but donor availability is limited.
• ABO-incompatible (ABO-i) and HLA-incompatible (HLAi) kidney transplantation programs address donor shortages, requiring pre-transplant desensitization.

Purpose of the Study:

• To evaluate the impact of pre-transplant desensitization protocols on the development of donor-specific antibodies (DSAs) in ABO-incompatible kidney transplantation.
• To understand the role of B-cell depleting therapies (rituximab) and splenectomy in modulating immune responses post-transplant.

Main Methods:

• Review of desensitization protocols for ABO-incompatible kidney transplantation.
• Analysis of the occurrence of donor-specific antibodies (DSAs) in patients undergoing different desensitization regimens.
• Comparison of outcomes between splenectomy (SPx) and rituximab (RTx) based desensitization strategies.

Main Results:

• Pre-transplant desensitization is mandatory for ABO-incompatible kidney transplantation.
• Rituximab and splenectomy interfere with B-cell function, potentially influencing immune responses.
• The study aims to determine if these interventions alter the incidence of post-transplant donor-specific alloantibodies.

Conclusions:

• Understanding the immunomodulatory effects of desensitization protocols is critical for optimizing ABO-incompatible kidney transplant outcomes.
• Further research is needed to clarify the long-term impact of rituximab and splenectomy on DSA formation and graft survival.